New Hairy Cell Leukemia Therapy Aims to Produce Complete Remissions
Robert J. Kreitman, MD, discusses key attributes of moxetumomab pasudotox and its potential impact in hairy cell leukemia.
More Data Needed on Changing Systemic Therapy in NSCLC
There is limited data on when and whether oncologists should change systemic therapy for patients with non–small cell lung cancer, but some studies provide useful guidance.
